Epithelial Thickness Is Marker for Gastroesophageal Reflux

Share this content:
Epithelial Thickness Is Marker for Gastroesophageal Reflux
Epithelial Thickness Is Marker for Gastroesophageal Reflux

FRIDAY, Oct. 28, 2016 (HealthDay News) -- Epithelial thickness seems to be a marker for gastroesophageal reflux disease (GERD), according to research published in the November issue of Clinical Gastroenterology and Hepatology.

Michael Vieth, M.D., Ph.D., from Klinikum Bayreuth in Germany, and colleagues performed a post-hoc analysis of data from the Diamond study conducted in Europe and Canada on adults with frequent upper gastrointestinal symptoms who had not taken a proton pump inhibitor in the previous two months. Biopsies were collected from 336 patients from 0.5 and 2.0 cm above the Z line and were analyzed independently at pathology centers in Germany and Italy.

The researchers found that total epithelial thickness was the best-performing criterion for diagnosis of investigation-defined GERD at the assessment site for basal cell layer thickness. At 0.5 and 2.0 cm above the Z line it also identified nonerosive reflux disease, reflux esophagitis, and pathologic esophageal acid exposure. Patients with GERD were not identified by basal cell layer thickness and presence of dilated intercellular spaces. Total epithelial thickness at 0.5 and 2.0 cm above the Z line had the best agreement between assessments carried out at the two pathology centers.

"Based on an analysis of 336 patients with frequent upper gastrointestinal symptoms, total epithelial thickness is a robust histologic marker for GERD," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca Gothenburg, which funded the study.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »